Overview Dividends

(EXPO) Exponent - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30214U1025

Consulting, Engineering, Sciences, Safety, Regulatory

EXPO EPS (Earnings per Share)

EPS Growth (3Y CAGR): 6.26%
EPS Trend (3Y Correlation): 21.1%

EXPO Revenue

Revenue Growth (3Y CAGR): -71.43%
Revenue Trend (3Y Correlation): -47.2%

Risk via 10d forecast
Volatility	26.3%
Value at Risk 5%th	40.1%

Reward
Sharpe Ratio	-1.62
Alpha Jensen	-45.92

Character
Hurst Exponent	0.255
Beta	0.911

Drawdowns 3y
Max DD	42.55%
Mean DD	19.91%

Description: EXPO Exponent November 08, 2025

Exponent, Inc. (NASDAQ: EXPO) is a science-and-engineering consulting firm that serves a broad spectrum of industries-including chemical, construction, consumer products, energy, food & beverage, government, life sciences, insurance, manufacturing, technology, transportation, and more-through two primary segments: Engineering & Other Scientific, and Environmental & Health.

The firm’s service portfolio spans biomechanics, biomedical engineering, civil & structural engineering, data science, electrical & computer engineering, human factors, materials & corrosion engineering, polymer science, thermal sciences, vehicle engineering, as well as chemical regulation, food safety, ecological and biological sciences, environmental & earth sciences, and health sciences. It also provides proactive and reactive product-safety, litigation-support, and regulatory consulting.

Key recent metrics (FY 2023): revenue of approximately $1.2 billion, operating margin around 12 %, and a backlog of roughly $1.0 billion, indicating a stable pipeline of multi-year contracts. The company’s litigation-support business has grown ~8 % YoY, driven by heightened product-liability activity across consumer and medical device sectors.

Macro-level drivers that could influence Exponent’s outlook include the U.S. Infrastructure Investment and Jobs Act, which is expected to boost demand for civil and structural engineering consulting, and tightening environmental regulations that increase the need for compliance and sustainability expertise across manufacturing and energy firms.

For a deeper dive into Exponent’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-rich overview worth checking out.

EXPO Stock Overview

Market Cap in USD	3,576m
Sub-Industry	Research & Consulting Services
IPO / Inception	1990-08-17
Return 12m vs S&P 500	-41.3%
Analyst Rating	3.67 of 5

EXPO Dividends

Dividend Yield	1.66%
Yield on Cost 5y	1.57%
Yield CAGR 5y	10.18%
Payout Consistency	100.0%
Payout Ratio	58.4%

EXPO Growth Ratios

CAGR	-10.14%
CAGR/Max DD Calmar Ratio	-0.24
CAGR/Mean DD Pain Ratio	-0.51
Current Volume	304.3k
Average Volume	335.9k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (104.8m TTM) > 0 and > 6% of Revenue (6% = 8.21m TTM)

FCFTA 0.21 (>2.0%) and ΔFCFTA 1.77pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 191.6% (prev 48.50%; Δ 143.1pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 129.3m > Net Income 104.8m (YES >=105%, WARN >=100%)

Net Debt (-124.8m) to EBITDA (137.4m) ratio: -0.91 <= 3.0 (WARN <= 3.5)

Current Ratio 2.69 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (51.5m) change vs 12m ago -0.33% (target <= -2.0% for YES)

Gross Margin -161.2% (prev 25.70%; Δ -186.9pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 20.80% (prev 76.16%; Δ -55.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -2.74 (EBITDA TTM 137.4m / Interest Expense TTM -38.6m) >= 6 (WARN >= 3)

Altman Z'' 9.78

(A) 0.46 = (Total Current Assets 416.8m - Total Current Liabilities 154.8m) / Total Assets 570.9m

(B) 1.15 = Retained Earnings (Balance) 658.8m / Total Assets 570.9m

warn (B) unusual magnitude: 1.15 — check mapping/units

(D) 1.83 = Book Value of Equity 656.5m / Total Liabilities 358.6m

Total Rating: 9.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.06

1. Piotroski 5.50pt = 0.50

2. FCF Yield 3.50% = 1.75

3. FCF Margin 88.42% = 7.50

4. Debt/Equity 0.21 = 2.48

5. Debt/Ebitda -0.91 = 2.50

6. ROIC - WACC (= 8.60)% = 10.75

7. RoE 24.77% = 2.06

8. Rev. Trend -47.19% = -3.54

9. EPS Trend 21.13% = 1.06

What is the price of EXPO shares?

As of November 12, 2025, the stock is trading at USD 70.95 with a total of 304,323 shares traded.
Over the past week, the price has changed by -1.05%, over one month by +7.73%, over three months by +2.17% and over the past year by -32.23%.

Is Exponent a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Exponent (NASDAQ:EXPO) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 75.06 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of EXPO is around 58.55 USD . This means that EXPO is currently overvalued and has a potential downside of -17.48%.

Is EXPO a buy, sell or hold?

Exponent has received a consensus analysts rating of 3.67. Therefor, it is recommend to hold EXPO.

Strong Buy: 1
Buy: 0
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EXPO price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	83	17%
Analysts Target Price	83	17%
ValueRay Target Price	65.8	-7.3%

EXPO Fundamental Data Overview November 02, 2025

Market Cap USD = 3.58b (3.58b USD * 1.0 USD.USD)
P/E Trailing = 34.8818
P/E Forward = 31.5457
P/S = 6.8881
P/B = 8.0313
P/EG = 3.14
Beta = 0.911
Revenue TTM = 136.8m USD
EBIT TTM = 105.9m USD
EBITDA TTM = 137.4m USD
Long Term Debt = 81.5m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 82.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.45b USD (3.58b + Debt 82.6m - CCE 207.4m)
Interest Coverage Ratio = -2.74 (Ebit TTM 105.9m / Interest Expense TTM -38.6m)
FCF Yield = 3.50% (FCF TTM 120.9m / Enterprise Value 3.45b)
FCF Margin = 88.42% (FCF TTM 120.9m / Revenue TTM 136.8m)
Net Margin = 76.65% (Net Income TTM 104.8m / Revenue TTM 136.8m)
Gross Margin = -161.2% ((Revenue TTM 136.8m - Cost of Revenue TTM 357.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev 16.43%)
Tobins Q-Ratio = 6.04 (Enterprise Value 3.45b / Total Assets 570.9m)
Interest Expense / Debt = 7.77% (Interest Expense 6.42m / Debt 82.6m)
Taxrate = 27.38% (10.6m / 38.6m)
NOPAT = 76.9m (EBIT 105.9m * (1 - 27.38%))
Current Ratio = 2.69 (Total Current Assets 416.8m / Total Current Liabilities 154.8m)
Debt / Equity = 0.21 (Debt 82.6m / totalStockholderEquity, last quarter 402.9m)
Debt / EBITDA = -0.91 (Net Debt -124.8m / EBITDA 137.4m)
Debt / FCF = -1.03 (Net Debt -124.8m / FCF TTM 120.9m)
Total Stockholder Equity = 423.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.36% (Net Income 104.8m / Total Assets 570.9m)
RoE = 24.77% (Net Income TTM 104.8m / Total Stockholder Equity 423.3m)
RoCE = 20.98% (EBIT 105.9m / Capital Employed (Equity 423.3m + L.T.Debt 81.5m))
RoIC = 17.88% (NOPAT 76.9m / Invested Capital 430.1m)
WACC = 9.29% (E(3.58b)/V(3.66b) * Re(9.37%) + D(82.6m)/V(3.66b) * Rd(7.77%) * (1-Tc(0.27)))
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 73.21% ; FCFE base≈130.3m ; Y1≈127.5m ; Y5≈129.6m
Fair Price DCF = 36.22 (DCF Value 1.83b / Shares Outstanding 50.5m; 5y FCF grow -3.13% → 3.0% )
EPS Correlation: 21.13 | EPS CAGR: 6.26% | SUE: -0.20 | # QB: 0
Revenue Correlation: -47.19 | Revenue CAGR: -71.43% | SUE: -4.0 | # QB: 0

Additional Sources for EXPO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle